, and the PLAT Study Group* The Progetto Lombardo Atero-Trombosi (PLAT) Study was a prospective, multicenter, multidisciplinary study of the association among hemostatic variables, conventional risk factors, and atherothrombotic events in four groups of patients with preexisting vascular ischemic disease (335 myocardial infarction survivors, 123 patients with stable angina pectoris, 160 with transient ischemic attacks, and 335 with peripheral vascular disease). In the myocardial infarction group, univariate analysis showed that atherothrombotic events were associated with high fibrinogen (p=0.001), factor VIII C (p<0.001), and von Willebrand factor antigen (vWF:Ag) (p=0.004) levels and with low high density lipoprotein cholesterol (p=0.043), factor VII (p=0.019), and protein C (p=0.044) levels; multivariate analysis produced associations with high fibrinogen and factor VIII: C levels and low protein C levels. By both univariate and multivariate analysis, events in the angina pectoris group were associated with high vWF:Ag (i=0.026) and leukocyte (p=0.033) levels and the presence of carotid arterial stenosis (p=0.063); associations with high leukocyte (p=0.037) and factor VIII :C (p=0.186) levels, family history (p=0.031), and diabetes (p=0.061) were also found in the group with transient ischemic attacks. In those with peripheral vascular disease, events were associated with Fontaine stage allB (p =0.024), high factor Vm:C levels (p=0.073), and low protein C (p=0.028), fibrinogen (p=0.030), antithrombin m (p=0.054), and factor VII (p=0.057) levels by univariate analysis and with Fontaine stage and low fibrinogen levels by multivariate analysis. In conclusion, the different associations observed in the four groups of patients may reflect a different hemostatic system involvement in the development of atherosclerosis and/or its clinical sequelae. ( 
that might better identify subjects at risk of ischemic sequelae is worthwhile. 13 The Progetto Lombardo Atero-Trombosi (PLAT) Study was a prospective cooperative study conducted by specialists in different fields, with the aim of assessing the association between hemostatic changes and the increased risk of fatal and nonfatal atherothrombotic events occurring during a 2-year follow-up period in a population with a history of ischemic disease in at least one of three main arterial territories.
Although the relations between the clinical manifestations of cardiac, cerebral, and peripheral atherosclerosis might reflect common risk factors, striking differences have been observed. 14 Thus, variables that are involved at various stages of hemostatic mechanisms may be expected to have somewhat different responses to atherosclerotic disease in different arterial beds. A single factor such as fibrinogen, for example, is not likely to represent the complex relation between the hemostatic system and the vessel wall. The PLAT Study explored this hypothesis by analyzing the prognostic value of various hemostatic variables in four groups of patients with myocardial infarction (MI), angina pecto-ris, transient ischemic attacks (TIAs), and peripheral vascular disease (PVD).
Methods

Study Plan and Design
A total of 953 patients (average age, 56.1 ±8.2 [mean±SD] years, 9.5% females) with documented atherosclerotic ischemic disease in at least one of three main vascular areas (coronary, cerebral, and peripheral) were enrolled from six specialized university and hospital centers in Milan and nearby towns. We recruited 335 MI survivors 3 months after the index event from two rehabilitation centers and 123 patients with stable angina pectoris within 7 days of a pathologydetermining coronary angiography from a single cardiology center. One hundred sixty patients with one or more TIAs (last ischemic event 3-12 months earlier) were enrolled from a single neurology center; the atherothrombotic nature of the TLA was ascertained by Doppler examination of the carotid arteries and/or cerebral angiography. Computed tomography or nuclear magnetic resonance imaging excluded causes other than cerebral ischemia. Three hundred thirty-five patients with PVD at Fontaine stages IIA (intermittent claudication, >1 block), IIB (intermittant claudication, < 1 block), or III (rest pain) underwent Doppler examination and were recruited from two vascular centers at least 3 months after any surgical procedures (endarterectomy or bypass). Oral informed consent was obtained from all patients.
The details of the study design and the basal characteristics of patients have been described elsewhere. 15 All patients were evaluated every 3 months for 2 years. No specific treatment protocol was proposed. Patient enrollment and follow-up was performed according to a common protocol, and compliance with the protocol was checked by a central committee that reviewed all the case records as well as end point events and accompanying documentation.
End Points
Documented atherothrombotic events in the three main vascular areas were considered as end points and were grouped for statistical analysis. End points included definite fatal and nonfatal MI (typical anterior chest pain, diagnostic electrocardiographic changes, or increase of cardiac enzymes above the upper limit of the reference range), sudden cardiac death (death within 60 minutes of onset of symptoms or an unobserved death), other cardiac deaths, fatal and nonfatal occlusive stroke, TLA (acute loss of focal cerebral or ocular function with symptoms lasting <24 hours), minor stroke (acute loss of focal cerebral or ocular function with symptoms lasting >24 hours but less than 7 days) documented by computed tomography or nuclear magnetic resonance imaging, acute peripheral ischemia requiring limb salvage, and peripheral bypass occlusion documented by angiography. End points were documented by reviewing hospital records and interviewing physicians and family members.
After a nonfatal end point event, patients continued their follow-up until the total 2-year period was completed; in the case of multiple events in the same patient, the first end point was considered in the statistical analysis.
Blood Analyses
Hemostatic tests, blood cell counts, and lipid and other routine biochemical hematology tests were done at the time of entry into the study and repeated 12 months later. This schedule was followed because in patients with atherosclerotic disease, hemostatic variables are necessarily imprecise if measured only once because of the within-person variability and the natural history of the disease and its dietary or pharmacological control.
In all patients the major processes of arterial thrombosis were investigated by factors representing the intrinsic (factor VIII coagulant [FVIII: C]) and extrinsic (factor VII [FVII]) coagulation pathways and their common substrate (fibrinogen) and by antithrombin III (AtlH) and protein C, which represent the major coagulation inhibitors. The von Wiilebrand factor antigen (vWF:Ag) was measured because it is a regulating factor in platelet adhesion to the vessel wall. In each participating center, blood was collected by a trained member of the medical staff. Blood samples for all tests were drawn by clean venipuncture without stasis with a 20-gauge needle from the antecubital vein between 8 and 9:30 AM after the subject had rested in the supine position for 10 minutes. For hemostatic tests, blood was collected into 3.8% trisodium citrate (9 volumes of blood to 1 volume of trisodium citrate solution) and immediately centrifuged at l,250g for 15 minutes at room temperature. The supernatant plasma was snapfrozen and stored in small aliquots at -80°C until assayed. For lipid assays, blood samples were collected into disposable tubes, and after coagulation, serum was separated and stored at -80°C.
Within 2 weeks, frozen plasma samples were transported in polystyrene containers with adequate amounts of dry ice to two central laboratories; one laboratory performed the coagulation tests and the other, the lipid assays. Transport did not take longer than 90 minutes. Tubes containing plasma were carefully inspected on arrival to ensure that the sample had not thawed and were then stored at -80°C. Eight samples with FVII levels >200%, suggesting cold activation during transport, were discarded.
At the time of assay, the frozen samples were transferred to a 37°C water bath and then handled at room temperature. A "plasma bank" was set up and maintained at -80°C, and plasma from this bank was used to perform more sophisticated studies with new methods.
Fibrinogen level was determined according to Clauss 16 by using Fibrinogen Reagent (Boehringer Mannheim). FVII and FVIII :C levels were determined by a one-stage biological assay using reagents and factor-deficient plasmas from Instrumentation Laboratory; reference curves were prepared daily by using the internal-standard pool. AtHI level was measured by a kinetic chromogenic method (Coatest Antithrombin, Ortho), and the results were expressed as percentages of the internal-standard plasma pool. vWF:Ag and protein C levels were determined with commercial enzyme-linked immunosorbent assays (Boehringer Mannheim), and the results were expressed as percentages of the internal-standard plasma pool. To reduce unwanted sources of variation, only one internal-standard pool of plasma obtained from 150 healthy blood donors, snap-frozen, and stored in liquid nitrogen was used throughout the study. All tests were carried out in duplicate by one member of the laboratory staff. Reagents from a single batch were used to avoid batch-to-batch variability. Day-to-day quality control was done by using Preciclot I and II (Boehringer Mannheim) for activated partial thromboplastin time (aPTT) and fibrinogen; the second international standard for FVIII-related activities in plasma 87/718 for FVTI, FVIII:C, vWF: Ag, and protein C; the first international reference preparation 12/1 for AtHI; and a commercial standard (Boehringer Mannheim) for protein C and vWF:Ag. A single batch of standard and control plasma was used. An aliquot of the internalstandard pool was also included as an unknown in each batch of assays.
Statistical Methods
Twenty-one variables were selected for analysis, including the laboratory tests (hematocrit, leukocyte count, fibrinogen, FVIII:C, FVII, aPTT, vWF: Ag, protein C, Atlll, total cholesterol, high density lipoprotein [HDL] cholesterol, and trigh/cerides) and the potential risk factors of age, sex (because about 20% of TIA patients were women), family history of cardiovascular disease, smoking habits, hypertension, diabetes, presence of carotid arterial stenosis >50% by Doppler ultrasonography, Fontaine stage, and ankle/arm pressure index.
Because the correlations between basal and 12-month laboratory values were highly significant (/><0.001 for each variable) and the differences between them were not significant, the mean of the two determinations was considered as each patient's characteristic value and was used in the analysis. For patients who were not tested at 12 months (withdrawal from the study or fatal end point), basal values were used in the analysis.
Continuous variables excluding age were adjusted to the standard age of 50 years by a linear-regression model. Ordinal variables were dichotomized (Fontaine stage ^Ila or SIIB, nonsmokers or current smokers). The four groups of patients were analyzed separately as defined by the study protocol. The impact of each variable on time to an end point was investigated by a series of simple regression analyses using the Cox proportional hazards model. 17 For each variable with a regression probability value of ^20%, the computed regression coefficient b was used to compute the standardized regression effect (SRE) and its 95% confidence interval as described by Meade et al. 10 For dichotomous variables the SRE is given by exp(b). Variables with/>^20% in the univariate regression were included in a stepwise multiple-regression analysis, in which variables were retained if the probability of their partial regression coefficient was ^20%; variables were added stepwise to the model until the overall probability was ^ 20%. The partial regression coefficients thus obtained were used to compute SREs and their confidence intervals.
Results
Eighty end points were observed during follow-up (Table 1) . Of the total number of patients, 9% withdrew from the study for nonmedical reasons (mainly because they moved to another area). In addition, nine patients died of causes unrelated to atherosclerosis (cancer in four cases, hepatic failure in two, car accident in one, and cerebral hemorrhage in one). Data for these patients obtained while they were enrolled in the study were used in the regression analyses, and the patients are included in the "no-end point" subgroup in the various tables. Table 2 reports the frequencies of demographic and clinical characteristics of the patients in the four groups and in the no-end point and end point subgroups, and Tables 3-6 report the clinical and laboratory variables associated with clinical outcome having a probability level of <10% for each patient group.
Myocardial Infarction
By univariate analysis, age (/?=0.017); higher levels of FVIII:C, vWF:Ag, and fibrinogen; and lower levels of FVII, protein C, and HDL cholesterol were associated with outcome, with a particularly strong association noted for FVIII:C. Four of these variables were selected in the stepwise regression analysis and were, in order of magnitude of their respective SREs, FVIII:C level, age (p=0.037), and protein C and fibrinogen levels. The MI group included 25.4% of patients who were on anticoagulant therapy. A separate analysis was performed excluding these patients, but the results did not differ from those obtained when the whole group was considered. 
Angina Pectoris
Univariate analysis revealed three variables with higher mean values or a higher proportion of cases in the end point subgroup that were associated with clinical outcome: vWF:Ag level, leukocyte level, and carotid artery abnormalities. All three variables were retained in the stepwise regression. Fibrinogen level, although not significantly associated with outcome (/?=0.136) in the univariate analysis, was the only other variable that qualified for inclusion in the multivariate analysis, but it was not retained by this procedure.
Transient Ischemic Attacks
By univariate analysis, an association with clinical outcome was found for leukocyte level, positive family history, and diabetes. Although not associated with outcome, FVIII: C also showed a higher mean value in the end point subgroup and qualified for inclusion in the multivariate analysis (p<0.20). This procedure retained all four variables. Compared with their SREs for univariate analysis, the SRE values decreased for diabetes and increased for the other three variables for multivariate analysis. 
Peripheral Vascular Disease
Significant univariate regressions were found for age (/?=0.011) and FVIII:C level (greater mean values in the end point subgroup); for severity of vascular disease (higher proportion of patients with Fontaine stage SIIB); and for protein C, fibrinogen, AtlH, and FVII levels (lower mean values in the end point subgroup). In addition, family history (/>=0.192) and triglyceride levels (p=0.192) qualified for inclusion in the multivariate analysis. Comparable results were obtained when patients with (n = l l l ) and without (n=224) previous surgical revascularization (at least 3 months before enrollment) were considered separately. Thus, nine variables were included in the stepwise regression analysis, and three were retained: age (/?=0.015), fibrinogen level, and Fontaine stage, the latter still having the greatest impact.
Discussion
The PLAT Study showed that FVIII:C, vWF:Ag, fibrinogen, and leukocyte levels were associated in various ways with subsequent atherothrombotic ischemic events in patients with atherosclerotic disease in different arterial beds. The aim of this study was to explore the relation between hemostatic variables and the ischemic events of atherothrombotic pathogenesis. Patients at low risk of fatal events were enrolled because it is difficult to establish the atherothrombotic nature of fatal events. Ninety-four and three tenths percent of MI patients were in Killip class I, no patient with complete irreversible stroke was included, and 97.3% of PVD patients were classified as Fontaine stage II; however, statistical evaluation was possible despite the relatively low number of events observed.
The PLAT protocol was written in 1985, and in line with the aims of the study, the methods chosen were already standardized and widely applicable to large populations. As in other previous epidemiological studies 9 -12 and in the ongoing ARIC study, 18 this excluded methods for the determination of prothrombin fragment 1+2 and protease inhibitor complexes; on the other hand, although activating peptides are indexes of clotting system activation, their use as predictive indexes in a large patient series has yet to be validated.
Platelet function and platelet activation factors (i.e., /3-thromboglobulin and platelet factor 4) were not studied because, as PLAT was a multicenter trial, it was impossible to satisfactorily standardize blood collection techniques and centrifugation of the samples. The novelty of PLAT lies in its multidisciplinary approach; its enrollment of patients with clinically evident atherosclerotic disease; its study of relations among hemostatic variables, traditional risk factors, and extent of vascular disease 1519 ; and its having identified an association between ischemic events and fibrinogen, FVLII, and leukocytes. The most important association was between FVIII:C, vWF: Ag, or both, and the incidence of clinical end points. These relations were found in all four groups at different levels of statistical significance. In MI survivors a rise of FVIII: C or vWF: Ag levels by one standard deviation was associated with a 70% increase in the incidence of atherothrombotic sequelae. In angina patients, vWF:Ag was the most important factor related to the incidence of clinical end points. In the TIA and PVD patients FVIII: C levels also tended to be higher in the end point subgroups. In a recent paper Jansson et al 20 report that a high concentration of vWF:Ag was a novel index of increased risk for reinfarction and mortality in a group of 123 MI survivors. Our results confirm the role of vWF: Ag as a risk factor not only for MI survivors but also for those in the other disease groups. The FVIII :C-vWF:Ag complex is essential for platelet adhesion to the arterial subendothelium. 21 v\VF:Ag binding with FVIII :C raises the concentration of FVIII: C at sites of vascular damage by preventing rapid removal of this procoagulant protein from the circulation.
The relation between leukocyte count and ischemic events in angina and TLA patients is intriguing. Indeed, a number of epidemiological and clinical studies (for review, see Reference 22) have shown a significant correlation between leukocyte count and vascular events. The role of leukocytes may be partially explained by their relation to other important risk factors. Indeed, the leukocyte count was higher in current smokers and was directly correlated with fibrinogen levels in our series. 15 A positive interaction between leukocytes and smoking was observed in our angina patients: one end point occurred in nonsmokers and five end points occurred in smokers, all of whom had leukocyte counts in the high tertile. However, the independent contribution of leukocytes observed by us is plausible on the basis of various studies demonstrating the important role of leukocytes in the pathophysiology of ischemia: they adhere to the endothelium, 23 release toxic oxygen compounds 24 and proteolytic enzymes, 25 interact with platelets, 26 and contribute to microvascular plugging. 27 - 28 More recently, Yarnell et al 12 have shown that leukocyte count is an independent risk factor for ischemic heart disease in both healthy subjects and men with preexisting disease. In our MI survivors the association between fibrinogen level and fatal and nonfatal vascular ischemic events was highly significant by univariate analysis (p=0.00l) but less evident with multistep regression analysis (p=0.066). The Northwick Park Heart Study 10 reported associations between high fibrinogen and FVII levels and increased risk of ischemic heart disease events in a healthy population. However, the relative risks decreased after adjusting for conventional risk factors. The predictive role of fibrinogen in the normal population was confirmed, but always with a lower independent significance by multivariate analysis. Ernst et al 32 observed that fibrinogen levels (estimated as the difference between plasma and serum viscosity) and other Theological factors were associated with prognosis in patients who were in the rehabilitation phase of complete stroke, whereas in the PLAT TLA patients, no association was found between fibrinogen level measured by the clotting method and clinical outcome.
Our study revealed no correlation between high FVII levels and end points. The significant association between low FVII levels and end points in the ML group by univariate analysis was not confirmed by stepwise selection. This association, as well as that with the natural anticoagulant protein C, was possibly influenced by the Cortellaro et al The PLAT Study 1069 use of anticoagulant therapy in 25% of the MI patients because both FVII and protein C are vitamin K dependent. Six of the 19 patients with a clinical end point were taking oral anticoagulants; however, when patients on anticoagulant therapy were excluded, FVII and protein C levels were still lower in the end point subgroup, although the differences were smaller.
In PVD patients the principal prognostic factor was the severity of arterial disease. Unexpectedly, we detected an inverse relation between fibrinogen level and clinical end points. In fact, a relation between fibrinogen level and PVD has been documented in crosssectional studies, 33 and basal fibrinogen levels of the PLAT patients (292.6 mg/dl versus 268.5 in the control subjects) confirm this association. However, very few studies have examined the outcome of PVD patients in terms of mortality and cardiovascular morbidity. Analysis of the 1,969 patients in the placebo group of the PACK trial showed that of the laboratory measurements performed at enrollment, initial leukocyte count was the only significant predictor of cardiovascular events.
3 * The localization of atherosclerotic lesions in different arteries (coronary or cerebral versus peripheral) may result in differences in lesion size, the interval between the appearance of lesions and the occurrence of critical thrombotic events, or both. Life-threatening lesions in the coronary and cerebral circulation may give rise to clinical thrombotic manifestations in a relatively short time, independent of lesion extent. Such manifestations may be favored by underlying conditions such as relative hyperfibrinogenemia. In contrast, peripheral arterial thrombi may form locally without causing critical clinical manifestations; thus, the vascular lesions can extend gradually. Longstanding interactions between hemostatic factors and extensive thrombogenic lesions may explain the lower levels of not only fibrinogen but also FVII, AtlH, and protein C in our PVD patients.
Although the low number of events does not allow us to propose definite conclusions, it is tempting to speculate that in coronary and cerebrovascular disease, an increased fibrinogen level may be viewed as a risk factor, whereas in peripheral disease, it serves more as an indicator of the stage of disease. This hypothesis needs further confirmation.
In conclusion, the PLAT Study results suggest that FVIII: C, vWF: Ag, fibrinogen, and leukocytes may be involved, together with some conventional risk factors such as age, smoking, and low HDL cholesterol level, in the multifactorial mechanism of atherothrombotic phenomena in patients with preexisting coronary or cerebrovascular disease. The different associations observed between vascular events, fibrinogen, FVIIIC, vWF: Ag, and leukocytes in the four groups of patients should help to clarify the relative significance of these variables in different atherosclerotic diseases. Whether these results reflect a different hemostatic system involvement in atherosclerosis development and/or the clinical sequelae remains to be established.
